10-K: Mangoceuticals, Inc. Reports Annual Results for Fiscal Year 2024, Navigating Challenges and Charting Future Growth

Mangoceuticals, Inc.'s 2024 annual report reveals a year of strategic shifts, including a subsidiary reorganization and patent acquisitions, amidst ongoing financial challenges and a net loss of $8.7 million.

Summary

• Mangoceuticals, Inc., a mens wellness company, reported its annual results for the fiscal year ended December 31, 2024.
• The company experienced a net loss of $8.7 million and an accumulated deficit of $20.8 million.
• Revenues decreased to $615,873 in 2024 from $731,493 in 2023, attributed to the transition to a new telehealth platform.
• The company is focusing on marketing its Pharmaceutical Products, including Mango ED, Grow, Mojo, and Slim, and PRIME by MangoRx, powered by Kyzatrex.
• A subsidiary reorganization was completed, contributing substantially all assets to Mango & Peaches Corp.
• The company acquired patents related to infection prevention and nutraceutical compositions, investing in research and development.
• The company is planning to license intellectual property related to plant-based formulations for skin brightening under the Dermytol brand.
• The company acknowledges the need for additional funding to support operations and potential acquisitions.
• The company is evaluating strategic alternatives to maximize shareholder value.
• The company faces risks related to competition, regulatory compliance, product liability, and data security.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments, such as patent acquisitions and new product development, the overall financial performance is weak, and the company faces significant risks and uncertainties. The going concern warning from the auditor is a major concern.

Positives

• The company is expanding its product line with new brands like Grow, Mojo, and Slim.
• The company is investing in research and development through patent acquisitions.
• The company is exploring new markets through international distribution agreements.
• The company is working to expand broad-based consumer access to PRIME, a FDA-approved oral Testosterone Replacement Therapy (TRT) product.

Negatives

• The company experienced a net loss of $8.7 million in 2024.
• The company has an accumulated deficit of $20.8 million as of December 31, 2024.
• The company's revenues decreased from $731,493 in 2023 to $615,873 in 2024.
• The company faces risks related to competition, regulatory compliance, product liability, and data security.
• The company's independent registered public accounting firm included an explanatory paragraph in its report on the consolidated financial statements as of December 31, 2024, indicating substantial doubt about its ability to continue as a going concern.

Risks

• The company needs additional funding to support its operations and may not be able to obtain it on favorable terms.
• The company faces intense competition from companies with greater resources and experience.
• The company's products have not been approved by the FDA and may cause serious side effects.
• The company relies on a related party pharmacy for compounding services.
• The company is subject to evolving government regulations and enforcement activities.
• The company may be subject to product liability claims and litigation.
• The company may experience disruptions in its data and information systems.
• The company's stock price may be volatile and could decline substantially.
• The company is an emerging growth company and may take advantage of reduced reporting requirements.
• The company is currently involved in litigation with Eli Lilly and Company.

Future Outlook

The company plans to continue using the same marketing and management strategies and continue providing a quality product with excellent customer service while also seeking to expand its operations organically or through acquisitions as funding and opportunities arise. The company is also conducting Phase II clinical trials and efficacy studies to determine the effectiveness of its patented respiratory illness prevention technology, with results expected in the 2nd quarter of 2025.

Industry Context

The company operates in the competitive mens wellness and telemedicine industries, facing competition from larger pharmaceutical companies and other online platforms. The company is attempting to differentiate itself through its branding, advertising, unique compounding, and product delivery system.

Comparison to Industry Standards

• The document mentions competitors like Hims & Hers Health, Inc., Roman, Pfizer (Viagra), Lilly ICOS LLC (Cialis), Merck & Co. (Propecia), and Johnson & Johnson (Rogaine).
• The document references market studies and reports from Verified Market Research, Grand View Research, The Insight Partners, and Mordor Intelligence LLP to provide context for the market size and growth potential of the erectile dysfunction and hair loss prevention products markets.
• The document references a Phase II clinical trial conducted by Ronald D. Wiehle and others, entitled Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone (Fertil Steril. 2014 Sep;102(3):720-7. doi: 10.1016/j.fertnstert.2014.06.004. Epub 2014 Jul 17. PMID: 25044085), which found enclomiphene citrate as being effective in increasing serum testosterone levels in hypogonadal men, as well as maintaining sperm counts.
• The document references a study conducted by Ratchathorn Panchaprateep & Suparuj Lueangarun, and published in the September 24, 2020 edition of Dermatology and Therapy, found that oral minoxidil at a dose of 5 mg taken once daily, significantly increased hair growth in men with AGA after 12 and 24 weeks of treatment (Panchaprateep, R., Lueangarun, S. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol Ther (Heidelb) 10, 13451357 (2020)).

Legal Proceedings

• Eli Lilly and Company filed a complaint against Mangoceuticals, Inc. alleging false and misleading advertising and promotion in violation of Section 43(a)(1)(B) of the Lanham Act; and false advertising, in connection with the Companys TRIM product.

Related Party Transactions

• The company has entered into a Master Services Agreement and Statement of Work and Consulting Agreement with Epiq Scripts, LLC, a related party, 52% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer, to provide pharmacy and compounding services.
• The company has previously received various related party loans and advances which are discussed in greater detail under Item 13. Certain Relationships and Related Transactions, and Director IndependenceRelated Party TransactionsRelated Party Loans and Advances .

Stakeholder Impact

• Shareholders may experience dilution from future equity issuances.
• Stakeholders face uncertainty due to the company's financial challenges and need for additional funding.
• Customers may benefit from the company's expanded product line and focus on mens wellness.
• Employees face potential risks related to the company's financial stability and ability to execute its business plan.

Next Steps

• Continue marketing and commercializing Pharmaceutical Products.
• Conduct Phase II clinical trials and efficacy testing on patented respiratory illness prevention technology.
• Prepare marketing and distribution strategy for Dermytol.
• Evaluate strategic alternatives to maximize shareholder value.
• Seek additional funding to support operations and potential acquisitions.

Key Dates

Keywords

Mangoceuticals, mens wellness, telemedicine, erectile dysfunction, hair loss, testosterone replacement therapy, weight management, pharmaceutical products, patent acquisition, financial results, risk factors, Epiq Scripts, Kyzatrex, Dermytol, Prime, Grow, Mojo, Slim